A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
NCT01020292
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Glioma
Interventions
DRUG:
Nelfinavir
Sponsor
Abramson Cancer Center at Penn Medicine